Renaissance Technologies
MTNB icon

Renaissance Technologies’s Matinas BioPharma MTNB Stock Holding History

Renaissance Technologies’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.5K Buy
71,040
+42,470
+149% +$27.4K ﹤0.01% 3058
2026
Q1 		$14.3K Sell
28,570
-400
-1% -$250 ﹤0.01% 3188
2025
Q4 		$17K Buy
28,970
+700
+2% +$825 ﹤0.01% 3154
2025
Q3 		$53.4K Buy
28,270
+3,600
+15% +$5.17K ﹤0.01% 3333
2025
Q2 		$22K Buy
24,670
+2,300
+10% +$1.69K ﹤0.01% 3466
2025
Q1 		$11.6K Buy
22,370
+4,200
+23% +$2.49K ﹤0.01% 3387
2024
Q4 		$9.27K Buy
+18,170
New +$27.6K ﹤0.01% 3521
2024
Q3 		– Sell
-8,943
Closed -$70.8K – 3764
2024
Q2 		$70.8K Buy
8,943
+662
+8% +$6K ﹤0.01% 3243
2024
Q1 		$112K Buy
8,281
+848
+11% +$10.1K ﹤0.01% 3348
2023
Q4 		$80K Buy
7,433
+3,146
+73% +$35.5K ﹤0.01% 3359
2023
Q3 		$28K Buy
4,287
+1,365
+47% +$16.8K ﹤0.01% 3482
2023
Q2 		$53K Sell
2,922
-517
-15% -$12.1K ﹤0.01% 3605
2023
Q1 		$81K Buy
3,439
+1,017
+42% +$25.7K ﹤0.01% 3551
2022
Q4 		$61K Buy
2,422
+1,746
+258% +$58.1K ﹤0.01% 3761
2022
Q3 		$21K Buy
+676
New +$26.6K ﹤0.01% 3892
2021
Q3 		– Sell
-12,183
Closed -$472K – 3709
2021
Q2 		$472K Buy
12,183
+9,375
+334% +$403K ﹤0.01% 2985
2021
Q1 		$147K Sell
2,808
-21,575
-88% -$1.45M ﹤0.01% 3190
2020
Q4 		$1.66M Buy
+24,383
New +$1.13M ﹤0.01% 2233
2020
Q3 		– Sell
-5,340
Closed -$206K – 3568
2020
Q2 		$206K Sell
5,340
-15,146
-74% -$581K ﹤0.01% 3149
2020
Q1 		$615K Buy
20,486
+14,527
+244% +$877K ﹤0.01% 2657
2019
Q4 		$676K Buy
+5,959
New +$345K ﹤0.01% 2790
2019
Q2 		– Sell
-5,060
Closed -$276K – 3688
2019
Q1 		$276K Buy
+5,060
New +$273K ﹤0.01% 3120
2018
Q4 		– Sell
-2,698
Closed -$124K – 3524
2018
Q3 		$124K Buy
2,698
+2,064
+326% +$44.4K ﹤0.01% 3222
2018
Q2 		$14K Buy
+634
New +$18.3K ﹤0.01% 3222

Other funds holding MTNB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies's MTNB Position: Q2 2026 in Review

Renaissance Technologies increased its Matinas BioPharma (MTNB) stake by 149% in Q2 2026, buying an estimated $27.4K and bringing the position to 71,040 shares worth $43.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3058.

Renaissance Technologies first reported a position in MTNB in Q2 2018 and has held it in 24 quarters since. The position peaked at $1.66M in Q4 2020. 20 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

  • Renaissance Technologies held 71,040 shares of Matinas BioPharma worth $43.5K as of Q2 2026.
  • Renaissance Technologies bought 42,470 Matinas BioPharma shares in Q2 2026, an estimated $27.4K.
  • Matinas BioPharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #3058 holding.
  • Renaissance Technologies first reported a position in Matinas BioPharma in Q2 2018 and has held it in 24 quarters since.
  • Renaissance Technologies's Matinas BioPharma position peaked at $1.66M in Q4 2020.
  • 20 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.